Sparrow Pharmaceuticals to Present New Pharmacology Data on SPI-62 at the 2022 Annual European Congress of Rheumatology

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new pharmacology data at the 2022 Annual European Congress of Rheumatology (EULAR) on its lead candidate, SPI-62, an HSD-1 inhibitor. SPI-47, a fixed-dose-combination of SPI-62 and prednisolone, is being developed for autoimmune and inflammatory diseases beginning with polymyalgia rheumatica. Sparrow will present the data during an in-person poster session. EULAR 2022 will take place 1-4 June 2022, at the Bella Center Copenhagen in Copenhagen, Denmark.

The poster presentation details are summarized below:

EULAR 2022 In-Person Poster Presentation

• Title: Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica

• Poster Number: POS1332

• Presenting Author: David A. Katz, Ph.D.

• Session Date/Time: 4 June, 2022
  • Dr. Katz will be in-person with the poster on 4 June at 10:15– 11:00 GMT +2
  • The poster will be displayed on Screen 123 in the EULAR Science Exhibit on 4 June at 8:45 - 9:30, 10:15– 11:00, 11:45 - 12:30, and 13:15 - 13:45 GMT +2
  • The poster and pre-recorded narration will also be available on the EULAR conference app from 1 June until 31 July

To register and view the abstracts, visit EULAR’s website here.

To learn more about Sparrow Pharmaceuticals and its leadership team, visit the website at www.sparrowpharma.com.

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into steroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions.SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues. SPI-47 is a fixed-dose-combination of SPI-62 and the glucocorticoid medicine prednisolone.